دورية أكاديمية
أعرض في EDS

Induction Therapy and Therapeutic Antibodies.

التفاصيل البيبلوغرافية
العنوان: Induction Therapy and Therapeutic Antibodies.
المؤلفون: Nikolova A; Smidt Cedars-Sinai Heart Institute, Los Angeles, CA, USA., Patel JK; Smidt Cedars-Sinai Heart Institute, Los Angeles, CA, USA. Jignesh.patel@cshs.org.
المصدر: Handbook of experimental pharmacology [Handb Exp Pharmacol] 2022; Vol. 272, pp. 85-116.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902231 Publication Model: Print Cited Medium: Print ISSN: 0171-2004 (Print) Linking ISSN: 01712004 NLM ISO Abbreviation: Handb Exp Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin, New York, Springer-Verlag.
مواضيع طبية MeSH: Graft Rejection*/prevention & control , Isoantibodies*, Antibodies, Monoclonal/therapeutic use ; Humans ; Immunosuppression Therapy ; Immunosuppressive Agents/therapeutic use ; Induction Chemotherapy
مستخلص: Prevention of allograft rejection is one of the crucial goals in solid organ transplantation to ensure durability of the graft and is chiefly mediated by cellular and humoral pathways targeting cell surface alloantigens. The risk of rejection is highest in the first post-transplant year and wanes with time albeit the risk always exists and varies with the type of organ transplanted. Induction therapies refer to the use of high-intensity immunosuppression in the immediate post-operative period to mitigate the highest risk of rejection. This term encompasses chiefly the use of antibody therapies directed against one of the key pathways in T-cell activation or abrogating effects of circulating alloantibodies. These antibodies carry more potent immunomodulatory effect than maintenance immunosuppressive therapy alone and many of them lead to durable immune cell depletion. A variety of monoclonal and polyclonal antibodies have been utilized for use not only for induction therapy, but also for treatment of allograft rejection when it occurs and as components of desensitization therapy before and after transplantation to modulate circulating alloantibodies.
(© 2022. Springer Nature Switzerland AG.)
References: Ansari D, Lund LH, Stehlik J, Andersson B, Hoglund P, Edwards L et al (2015a) Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. J Heart Lung Transplant 34(10):1283–1291. https://doi.org/10.1016/j.healun.2015.04.001. (PMID: 10.1016/j.healun.2015.04.00126087667)
Ansari D, Hoglund P, Andersson B, Nilsson J (2015b) Comparison of basiliximab and anti-thymocyte globulin as induction therapy in pediatric heart transplantation: a survival analysis. J Am Heart Assoc 5(1). https://doi.org/10.1161/JAHA.115.002790.
Benazzo A, Schwarz S, Muckenhuber M, Schweiger T, Murakozy G, Moser B et al (2019) Alemtuzumab induction combined with reduced maintenance immunosuppression is associated with improved outcomes after lung transplantation: a single Centre experience. PLoS One 14(1):e0210443. https://doi.org/10.1371/journal.pone.0210443. (PMID: 10.1371/journal.pone.0210443306456456333331)
Bittermann T, Hubbard RA, Lewis JD, Goldberg DS (2019) The use of induction therapy in liver transplantation is highly variable and is associated with posttransplant outcomes. Am J Transplant 19(12):3319–3327. https://doi.org/10.1111/ajt.15513. (PMID: 10.1111/ajt.15513312438876883120)
Bonnefoy-Berard N, Vincent C, Revillard JP (1991) Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 51(3):669–673. https://doi.org/10.1097/00007890-199103000-00024. (PMID: 10.1097/00007890-199103000-000242006524)
Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L et al (2018a) De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant 18(7):1783–1789. https://doi.org/10.1111/ajt.14721. (PMID: 10.1111/ajt.14721295092956055714)
Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L et al (2018b) Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT. Am J Transplant 18(7):1774–1782. https://doi.org/10.1111/ajt.14738. (PMID: 10.1111/ajt.14738295733356055813)
Brennan DC, Schnitzler MA (2008) Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 359(16):1736–1738. https://doi.org/10.1056/NEJMc0805714. (PMID: 10.1056/NEJMc080571418923181)
Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group (2006) Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355(19):1967–1977. https://doi.org/10.1056/NEJMoa060068. (PMID: 10.1056/NEJMoa06006817093248)
Briasoulis A, Inampudi C, Pala M, Asleh R, Alvarez P, Bhama J (2018) Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis. Heart Fail Rev 23(5):641–649. https://doi.org/10.1007/s10741-018-9691-2. (PMID: 10.1007/s10741-018-9691-229532201)
Brook MO, Wood KJ, Jones ND (2006) The impact of memory T cells on rejection and the induction of tolerance. Transplantation 82(1):1–9. https://doi.org/10.1097/01.tp.0000226082.17507.da. (PMID: 10.1097/01.tp.0000226082.17507.da16861933)
Carrier M, Leblanc MH, Perrault LP, White M, Doyle D, Beaudoin D et al (2007) Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 26(3):258–263. https://doi.org/10.1016/j.healun.2007.01.006. (PMID: 10.1016/j.healun.2007.01.00617346628)
Chih S, Patel J (2016) Desensitization strategies in adult heart transplantation-will persistence pay off? J Heart Lung Transplant 35(8):962–972. https://doi.org/10.1016/j.healun.2016.03.021. (PMID: 10.1016/j.healun.2016.03.02127216504)
Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D et al (2017) Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 17(9):2381–2389. https://doi.org/10.1111/ajt.14228. (PMID: 10.1111/ajt.1422828199785)
Chong AS, Alegre ML (2012) The impact of infection and tissue damage in solid-organ transplantation. Nat Rev Immunol 12(6):459–471. https://doi.org/10.1038/nri3215. (PMID: 10.1038/nri3215226278624053185)
Cippa PE, Schiesser M, Ekberg H, van Gelder T, Mueller NJ, Cao CA et al (2015) Risk stratification for rejection and infection after kidney transplantation. Clin J Am Soc Nephrol 10(12):2213–2220. https://doi.org/10.2215/CJN.01790215. (PMID: 10.2215/CJN.01790215264300884670759)
Colvin M, Smith JM, Ahn Y, Skeans MA, Messick E, Goff R et al (2021) OPTN/SRTR 2019 annual data report: heart. Am J Transplant 21(Suppl 2):356–440. https://doi.org/10.1111/ajt.16492. (PMID: 10.1111/ajt.1649233595196)
Cornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD (2015) Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 15(5):1293–1302. https://doi.org/10.1111/ajt.13168. (PMID: 10.1111/ajt.1316825731800)
Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H et al (2021) A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 32(3):708–722. https://doi.org/10.1681/ASN.2020071106. (PMID: 10.1681/ASN.202007110633443079)
Ducloux D, Courivaud C, Bamoulid J, Vivet B, Chabroux A, Deschamps M et al (2010) Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation. J Am Soc Nephrol 21(5):868–875. https://doi.org/10.1681/ASN.2009090976. (PMID: 10.1681/ASN.2009090976202031602865743)
Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J et al (2010) A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 10(3):547–557. https://doi.org/10.1111/j.1600-6143.2010.03016.x. (PMID: 10.1111/j.1600-6143.2010.03016.x20415898)
Enderby C, Keller CA (2015) An overview of immunosuppression in solid organ transplantation. Am J Manag Care 21(1 Suppl):s12–s23. (PMID: 25734416)
Furuya Y, Jayarajan SN, Taghavi S, Cordova FC, Patel N, Shiose A et al (2016) The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients. Am J Transplant 16(8):2334–2341. https://doi.org/10.1111/ajt.13739. (PMID: 10.1111/ajt.1373926833657)
Gale SE, Ravichandran B, Ton VK, Pham S, Reed BN (2019) Alemtuzumab induction versus conventional immunosuppression in heart transplant recipients. J Cardiovasc Pharmacol Ther 24(5):435–441. https://doi.org/10.1177/1074248419841635. (PMID: 10.1177/107424841984163531035777)
Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, Chadban S et al (2019) Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. Am J Transplant 19(10):2865–2875. https://doi.org/10.1111/ajt.15397. (PMID: 10.1111/ajt.1539731012541)
Gralla J, Wiseman AC (2010) The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. Transplantation 90(6):639–644. https://doi.org/10.1097/TP.0b013e3181ea6788. (PMID: 10.1097/TP.0b013e3181ea678820595929)
Group CSC, Haynes R, Harden P, Judge P, Blackwell L, Emberson J et al (2014) Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C study): a randomised trial. Lancet 384(9955):1684–1690. https://doi.org/10.1016/S0140-6736(14)61095-3. (PMID: 10.1016/S0140-6736(14)61095-3)
Hachem RR, Edwards LB, Yusen RD, Chakinala MM, Alexander Patterson G, Trulock EP (2008) The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. Clin Transpl 22(5):603–608. https://doi.org/10.1111/j.1399-0012.2008.00831.x. (PMID: 10.1111/j.1399-0012.2008.00831.x)
Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351(26):2715–2729. https://doi.org/10.1056/NEJMra033540. (PMID: 10.1056/NEJMra03354015616206)
Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR et al (2011) Alemtuzumab induction in renal transplantation. N Engl J Med 364(20):1909–1919. https://doi.org/10.1056/NEJMoa1009546. (PMID: 10.1056/NEJMoa100954621591943)
Hart A, Lentine KL, Smith JM, Miller JM, Skeans MA, Prentice M et al (2021) OPTN/SRTR 2019 annual data report: kidney. Am J Transplant 21(Suppl 2):21–137. https://doi.org/10.1111/ajt.16502. (PMID: 10.1111/ajt.1650233595191)
Hellemans R, Bosmans JL, Abramowicz D (2017) Induction therapy for kidney transplant recipients: do we still need anti-IL2 receptor monoclonal antibodies? Am J Transplant 17(1):22–27. https://doi.org/10.1111/ajt.13884. (PMID: 10.1111/ajt.1388427223882)
Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC (2017) Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst Rev (1):CD004759. https://doi.org/10.1002/14651858.CD004759.pub2.
Horslen SP, Smith JM, Ahn Y, Skeans MA, Cafarella M, Noreen SM et al (2021) OPTN/SRTR 2019 annual data report: intestine. Am J Transplant 21(Suppl 2):316–355. https://doi.org/10.1111/ajt.16498. (PMID: 10.1111/ajt.1649833595193)
Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16(5):448–457. https://doi.org/10.1038/ni.3153. (PMID: 10.1038/ni.315325898198)
Ingulli E (2010) Mechanism of cellular rejection in transplantation. Pediatr Nephrol 25(1):61–74. https://doi.org/10.1007/s00467-008-1020-x. (PMID: 10.1007/s00467-008-1020-x214762312778785)
Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the innate immune system. Science 327(5963):291–295. https://doi.org/10.1126/science.1183021. (PMID: 10.1126/science.1183021200752443645875)
Jackson AM, Kraus ES, Orandi BJ, Segev DL, Montgomery RA, Zachary AA (2015) A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int 87(2):409–416. https://doi.org/10.1038/ki.2014.261. (PMID: 10.1038/ki.2014.26125054778)
Jaksch P, Ankersmit J, Scheed A, Kocher A, Murakozy G, Klepetko W et al (2014) Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. Am J Transplant 14(8):1839–1845. https://doi.org/10.1111/ajt.12824. (PMID: 10.1111/ajt.1282425039364)
Jeong JC, Jambaldorj E, Kwon HY, Kim MG, Im HJ, Jeon HJ et al (2016) Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation. Medicine (Baltimore) 95(5):e2635. https://doi.org/10.1097/MD.0000000000002635. (PMID: 10.1097/MD.0000000000002635)
Joher N, Matignon M, Grimbert P (2021) HLA desensitization in solid organ transplantation: anti-CD38 to across the immunological barriers. Front Immunol 12:688301. https://doi.org/10.3389/fimmu.2021.688301. (PMID: 10.3389/fimmu.2021.688301340935948173048)
John R, Lietz K, Burke E, Ankersmit J, Mancini D, Suciu-Foca N et al (1999) Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 100(19 Suppl):II229–II235. https://doi.org/10.1161/01.cir.100.suppl_2.ii-229. (PMID: 10.1161/01.cir.100.suppl_2.ii-22910567309)
John R, Lietz K, Burke E, Schuster M, Yen E, Naka Y et al (2001) Intravenous immunoglobulin therapy in highly sensitized cardiac allograft recipients facilitates transplantation across donor specific IGG positive cross matches. J Heart Lung Transplant 20(2):213. https://doi.org/10.1016/s1053-2498(00)00463-0. (PMID: 10.1016/s1053-2498(00)00463-011250390)
Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A et al (2004) Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15(12):3256–3262. https://doi.org/10.1097/01.ASN.0000145878.92906.9F. (PMID: 10.1097/01.ASN.0000145878.92906.9F15579530)
Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B et al (2017) Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation 101(1):32–44. https://doi.org/10.1097/TP.0000000000001452. (PMID: 10.1097/TP.000000000000145227547870)
Jordan SC, Ammerman N, Choi J, Kumar S, Huang E, Toyoda M et al (2020) Interleukin-6: an important mediator of allograft injury. Transplantation 104(12):2497–2506. https://doi.org/10.1097/TP.0000000000003249. (PMID: 10.1097/TP.000000000000324932235253)
Kahan BD, Rajagopalan PR, Hall M (1999) Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 67(2):276–284. https://doi.org/10.1097/00007890-199901270-00016. (PMID: 10.1097/00007890-199901270-0001610075594)
Kahwaji J, Jordan SC, Najjar R, Wongsaroj P, Choi J, Peng A et al (2016) Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transpl Int 29(12):1276–1285. https://doi.org/10.1111/tri.12832. (PMID: 10.1111/tri.1283227529314)
Kainz A, Korbely R, Soleiman A, Mayer B, Oberbauer R (2010) Antithymocyte globulin use for treatment of biopsy confirmed acute rejection is associated with prolonged renal allograft survival. Transpl Int 23(1):64–70. https://doi.org/10.1111/j.1432-2277.2009.00950.x. (PMID: 10.1111/j.1432-2277.2009.00950.x19719467)
Kandaswamy R, Stock PG, Miller J, Skeans MA, White J, Wainright J et al (2021) OPTN/SRTR 2019 annual data report: pancreas. Am J Transplant 21(Suppl 2):138–207. https://doi.org/10.1111/ajt.16496. (PMID: 10.1111/ajt.1649633595197)
Kaufman DB, Woodle ES, Shields AR, Leone J, Matas A, Wiseman A et al (2021) Belatacept for simultaneous calcineurin inhibitor and chronic corticosteroid immunosuppression avoidance: two-year results of a prospective, randomized multicenter trial. Clin J Am Soc Nephrol 16(9):1387–1397. https://doi.org/10.2215/CJN.13100820. (PMID: 10.2215/CJN.1310082034233921)
Kidney Disease: Improving Global Outcomes Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–S155. https://doi.org/10.1111/j.1600-6143.2009.02834.x. (PMID: 10.1111/j.1600-6143.2009.02834.x)
Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M et al (1995) The OKT3 antibody response study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transpl Immunol 3(3):212–221. https://doi.org/10.1016/0966-3274(95)80027-1. (PMID: 10.1016/0966-3274(95)80027-18581409)
Kittleson MM, Patel N, Chang DH, Kransdorf EP, Kobashigawa JA, Patel JK (2021) Eculizumab for antibody-mediated rejection in heart transplantation: a case-control study. Clin Transpl. https://doi.org/10.1111/ctr.14454.
Klintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Agnes S et al (2014) Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant 14(8):1817–1827. https://doi.org/10.1111/ajt.12810. (PMID: 10.1111/ajt.12810250413394140547)
Kobashigawa JA, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Davis SN et al (2011) The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transpl 25(1):E61–E67. https://doi.org/10.1111/j.1399-0012.2010.01334.x. (PMID: 10.1111/j.1399-0012.2010.01334.x)
Kumar D, LeCorchick S, Gupta G (2017) Belatacept as an alternative to calcineurin inhibitors in patients with solid organ transplants. Front Med (Lausanne) 4:60. https://doi.org/10.3389/fmed.2017.00060. (PMID: 10.3389/fmed.2017.00060)
Kwong AJ, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA et al (2021) OPTN/SRTR 2019 annual data report: liver. Am J Transplant 21(Suppl 2):208–315. https://doi.org/10.1111/ajt.16494. (PMID: 10.1111/ajt.1649433595192)
Laftavi MR, Pankewycz O, Feng L, Said M, Patel S (2015) Combined induction therapy with rabbit antithymocyte globulin and rituximab in highly sensitized renal recipients. Immunol Investig 44(4):373–384. https://doi.org/10.3109/08820139.2015.1014097. (PMID: 10.3109/08820139.2015.1014097)
Leech SH, Lopez-Cepero M, LeFor WM, DiChiara L, Weston M, Furukawa S et al (2006) Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transpl 20(4):476–484. https://doi.org/10.1111/j.1399-0012.2006.00509.x. (PMID: 10.1111/j.1399-0012.2006.00509.x)
Li KHC, Ho JCS, Recaldin B, Gong M, Ho J, Li G et al (2018) Acute cellular rejection and infection rates in alemtuzumab vs traditional induction therapy agents for lung and heart transplantation: a systematic review and meta-analysis. Transplant Proc 50(10):3723–3731. https://doi.org/10.1016/j.transproceed.2018.08.044. (PMID: 10.1016/j.transproceed.2018.08.04430577263)
Lim WH, Chadban SJ, Campbell S, Dent H, Russ GR, McDonald SP (2010) Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients. Nephrology (Carlton) 15(3):368–376. https://doi.org/10.1111/j.1440-1797.2009.01259.x. (PMID: 10.1111/j.1440-1797.2009.01259.x)
Linder KA, Kauffman CA, Patel TS, Fitzgerald LJ, Richards BJ, Miceli MH (2021) Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation. Transpl Infect Dis 23(1):e13448. https://doi.org/10.1111/tid.13448. (PMID: 10.1111/tid.1344833448560)
Loupy A, Suberbielle-Boissel C, Zuber J, Anglicheau D, Timsit MO, Martinez F et al (2010) Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 89(11):1403–1410. https://doi.org/10.1097/TP.0b013e3181da1cc3. (PMID: 10.1097/TP.0b013e3181da1cc320386362)
Malvezzi P, Jouve T, Rostaing L (2015) Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage. J Nephropathol 4(4):110–115. https://doi.org/10.12860/jnp.2015.21. (PMID: 10.12860/jnp.2015.21264572574596294)
Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M et al (2004) Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 78(7):966–971. https://doi.org/10.1097/01.tp.0000142674.78268.01. (PMID: 10.1097/01.tp.0000142674.78268.01154801602993510)
Mariat C, Alamartine E, Diab N, de Filippis JP, Laurent B, Berthoux F (1998) A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transpl Int 11(3):231–236. https://doi.org/10.1007/s001470050133. (PMID: 10.1007/s0014700501339638854)
Masson P, Henderson L, Chapman JR, Craig JC, Webster AC (2014) Belatacept for kidney transplant recipients. Cochrane Database Syst Rev (11):CD010699. https://doi.org/10.1002/14651858.CD010699.pub2.
Mattei MF, Redonnet M, Gandjbakhch I, Bandini AM, Billes A, Epailly E et al (2007) Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 26(7):693–699. https://doi.org/10.1016/j.healun.2007.05.002. (PMID: 10.1016/j.healun.2007.05.00217613399)
Meier-Kriesche HU, Arndorfer JA, Kaplan B (2002) Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 13(3):769–772. https://doi.org/10.1681/ASN.V133769. (PMID: 10.1681/ASN.V13376911856783)
Moini M, Schilsky ML, Tichy EM (2015) Review on immunosuppression in liver transplantation. World J Hepatol 7(10):1355–1368. https://doi.org/10.4254/wjh.v7.i10.1355. (PMID: 10.4254/wjh.v7.i10.1355260523814450199)
Moller CH, Gustafsson F, Gluud C, Steinbruchel DA (2008) Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials. J Heart Lung Transplant 27(8):835–842. https://doi.org/10.1016/j.healun.2008.05.013. (PMID: 10.1016/j.healun.2008.05.01318656795)
Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE et al (2011) Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 365(4):318–326. https://doi.org/10.1056/NEJMoa1012376. (PMID: 10.1056/NEJMoa101237621793744)
Moreau A, Varey E, Anegon I, Cuturi MC (2013) Effector mechanisms of rejection. Cold Spring Harb Perspect Med 3(11). https://doi.org/10.1101/cshperspect.a015461.
Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8(12):958–969. https://doi.org/10.1038/nri2448. (PMID: 10.1038/nri2448190299902724991)
Nankivell BJ, Alexander SI (2010) Rejection of the kidney allograft. N Engl J Med 363(15):1451–1462. https://doi.org/10.1056/NEJMra0902927. (PMID: 10.1056/NEJMra090292720925547)
Noel C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M et al (2009) Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 20(6):1385–1392. https://doi.org/10.1681/ASN.2008101037. (PMID: 10.1681/ASN.2008101037194706772689909)
Palmer WC, Taner CB, Keaveny AP, Nakhleh RE, Nguyen JH, Rosser BG Jr (2018) Antithymocyte globulin use for corticosteroid nonresponsive rejection after liver transplantation. Transplant Proc 50(10):3606–3614. https://doi.org/10.1016/j.transproceed.2018.09.001. (PMID: 10.1016/j.transproceed.2018.09.00130577245)
Patel JK, Coutance G, Loupy A, Dilibero D, Hamilton M, Kittleson M et al (2021) Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. Am J Transplant 21(7):2479–2488. https://doi.org/10.1111/ajt.16420. (PMID: 10.1111/ajt.1642033251691)
Pereira M, Guerra J, Neves M, Goncalves J, Santana A, Nascimento C et al (2016) Predictive factors of acute rejection in low immunologic risk kidney transplant recipients receiving basiliximab. Transplant Proc 48(7):2280–2283. https://doi.org/10.1016/j.transproceed.2016.06.022. (PMID: 10.1016/j.transproceed.2016.06.02227742279)
Pisani BA, Mullen GM, Malinowska K, Lawless CE, Mendez J, Silver MA et al (1999) Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 18(7):701–706. https://doi.org/10.1016/s1053-2498(99)00022-4. (PMID: 10.1016/s1053-2498(99)00022-410452347)
Post DJ, Douglas DD, Mulligan DC (2005) Immunosuppression in liver transplantation. Liver Transpl 11(11):1307–1314. https://doi.org/10.1002/lt.20614. (PMID: 10.1002/lt.2061416237688)
Preville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J et al (2001) Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 71(3):460–468. https://doi.org/10.1097/00007890-200102150-00021. (PMID: 10.1097/00007890-200102150-0002111233911)
Reams BD, Musselwhite LW, Zaas DW, Steele MP, Garantziotis S, Eu PC et al (2007) Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant 7(12):2802–2808. https://doi.org/10.1111/j.1600-6143.2007.02000.x. (PMID: 10.1111/j.1600-6143.2007.02000.x17924993)
Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N et al (2019) Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. Am J Transplant 19(11):3035–3045. https://doi.org/10.1111/ajt.15514. (PMID: 10.1111/ajt.15514312577246899639)
Ruzek MC, Neff KS, Luong M, Smith KA, Culm-Merdek K, Richards SM et al (2009) In vivo characterization of rabbit anti-mouse thymocyte globulin: a surrogate for rabbit anti-human thymocyte globulin. Transplantation 88(2):170–179. https://doi.org/10.1097/TP.0b013e3181abc061. (PMID: 10.1097/TP.0b013e3181abc06119623011)
Scheffert JL, Raza K (2014) Immunosuppression in lung transplantation. J Thorac Dis 6(8):1039–1053. https://doi.org/10.3978/j.issn.2072-1439.2014.04.23. (PMID: 10.3978/j.issn.2072-1439.2014.04.23251329714133546)
Shah A, Nadasdy T, Arend L, Brennan J, Leong N, Coppage M et al (2004) Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 77(9):1399–1405. https://doi.org/10.1097/01.tp.0000122187.76518.bc. (PMID: 10.1097/01.tp.0000122187.76518.bc15167598)
Shehata N, Palda VA, Meyer RM, Blydt-Hansen TD, Campbell P, Cardella C et al (2010) The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev 24(Suppl 1):S7–S27. https://doi.org/10.1016/j.tmrv.2009.09.010. (PMID: 10.1016/j.tmrv.2009.09.01019962580)
Smith C, Miles JJ, Khanna R (2012) Advances in direct T-cell alloreactivity: function, avidity, biophysics and structure. Am J Transplant 12(1):15–26. https://doi.org/10.1111/j.1600-6143.2011.03863.x. (PMID: 10.1111/j.1600-6143.2011.03863.x22152064)
Smyth LA, Herrera OB, Golshayan D, Lombardi G, Lechler RI (2006) A novel pathway of antigen presentation by dendritic and endothelial cells: implications for allorecognition and infectious diseases. Transplantation 82(1 Suppl):S15–S18. https://doi.org/10.1097/01.tp.0000231347.06149.ca. (PMID: 10.1097/01.tp.0000231347.06149.ca16829787)
SRTR (2019) Annual data report. Scientific Registry of Transplant Recipients 2019. http://srtr.transplant.hrsa.gov/annual_reports/Default.aspx . Accessed 16 Sep 2021.
Starling RC, Armstrong B, Bridges ND, Eisen H, Givertz MM, Kfoury AG et al (2019) Accelerated allograft vasculopathy with rituximab after cardiac transplantation. J Am Coll Cardiol 74(1):36–51. https://doi.org/10.1016/j.jacc.2019.04.056. (PMID: 10.1016/j.jacc.2019.04.05631272550)
Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG et al (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11(11):2405–2413. https://doi.org/10.1111/j.1600-6143.2011.03757.x. (PMID: 10.1111/j.1600-6143.2011.03757.x21942930)
Tan EK, Bentall A, Dean PG, Shaheen MF, Stegall MD, Schinstock CA (2019) Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases. Transplantation 103(11):2397–2404. https://doi.org/10.1097/TP.0000000000002639. (PMID: 10.1097/TP.0000000000002639308015496699919)
Tanaka T, Kishimoto T (2014) The biology and medical implications of interleukin-6. Cancer Immunol Res 2(4):288–294. https://doi.org/10.1158/2326-6066.CIR-14-0022. (PMID: 10.1158/2326-6066.CIR-14-002224764575)
Tanriover B, Zhang S, MacConmara M, Gao A, Sandikci B, Ayvaci MU et al (2015) Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance. Clin J Am Soc Nephrol 10(6):1041–1049. https://doi.org/10.2215/CJN.08710814. (PMID: 10.2215/CJN.08710814259799714455215)
Teuteberg JJ, Shullo MA, Zomak R, Toyoda Y, McNamara DM, Bermudez C et al (2010) Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 10(2):382–388. https://doi.org/10.1111/j.1600-6143.2009.02856.x. (PMID: 10.1111/j.1600-6143.2009.02856.x19889126)
Todd JL, Palmer SM (2014) Alemtuzumab induction in lung transplantation: time to move on? Am J Transplant 14(8):1721–1722. https://doi.org/10.1111/ajt.12825. (PMID: 10.1111/ajt.1282525039475)
Valapour M, Lehr CJ, Skeans MA, Smith JM, Miller E, Goff R et al (2021) OPTN/SRTR 2019 annual data report: lung. Am J Transplant 21(Suppl 2):441–520. https://doi.org/10.1111/ajt.16495. (PMID: 10.1111/ajt.1649533595190)
Valenzuela NM, Reed EF (2017) Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. J Clin Invest 127(7):2492–2504. https://doi.org/10.1172/JCI90597. (PMID: 10.1172/JCI90597286043845490786)
van den Hoogen MW, Kamburova EG, Baas MC, Steenbergen EJ, Florquin S, Koenen HJPM et al (2015) Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant 15(2):407–416. https://doi.org/10.1111/ajt.13052. (PMID: 10.1111/ajt.1305225612493)
van der Zwan M, Clahsen-Van Groningen MC, van den Hoogen MWF, Kho MML, Roodnat JI, Mauff KAL et al (2020) Comparison of alemtuzumab and anti-thymocyte globulin treatment for acute kidney allograft rejection. Front Immunol 11:1332. https://doi.org/10.3389/fimmu.2020.01332. (PMID: 10.3389/fimmu.2020.01332327196767350932)
Vanderlugt CL, Miller SD (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2(2):85–95. https://doi.org/10.1038/nri724. (PMID: 10.1038/nri72411910899)
Vathsala A, Ona ET, Tan SY, Suresh S, Lou HX, Casasola CB et al (2005) Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80(6):765–774. https://doi.org/10.1097/01.tp.0000166921.14670.33. (PMID: 10.1097/01.tp.0000166921.14670.3316210963)
Vincenti F (2016) Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374(26):2600–2601. https://doi.org/10.1056/NEJMc1602859. (PMID: 10.1056/NEJMc160285927355541)
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P et al (2010a) A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10(3):535–546. https://doi.org/10.1111/j.1600-6143.2009.03005.x. (PMID: 10.1111/j.1600-6143.2009.03005.x20415897)
Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF et al (2010b) Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 21(9):1587–1596. https://doi.org/10.1681/ASN.2009111109. (PMID: 10.1681/ASN.2009111109206342983013525)
Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L et al (2016) Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374(4):333–343. https://doi.org/10.1056/NEJMoa1506027. (PMID: 10.1056/NEJMoa150602726816011)
Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH et al (2008) Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359(3):242–251. https://doi.org/10.1056/NEJMoa0707894. (PMID: 10.1056/NEJMoa070789418635429)
Vo AA, Petrozzino J, Yeung K, Sinha A, Kahwaji J, Peng A et al (2013) Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 95(6):852–858. https://doi.org/10.1097/TP.0b013e3182802f88. (PMID: 10.1097/TP.0b013e3182802f8823511212)
Vo AA, Choi J, Kim I, Louie S, Cisneros K, Kahwaji J et al (2015) A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation 99(11):2356–2363. https://doi.org/10.1097/TP.0000000000000741. (PMID: 10.1097/TP.000000000000074126018350)
Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR et al (2005) Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Am J Transplant 5(6):1347–1353. https://doi.org/10.1111/j.1600-6143.2005.00822.x. (PMID: 10.1111/j.1600-6143.2005.00822.x15888040)
Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS et al (2010) Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev (1):CD003897. https://doi.org/10.1002/14651858.CD003897.pub3.
Yelken B, Arpali E, Gorcin S, Kocak B, Karatas C, Demiralp E et al (2015) Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-Center experience. Transplant Proc 47(6):1754–1759. https://doi.org/10.1016/j.transproceed.2015.06.029. (PMID: 10.1016/j.transproceed.2015.06.02926293046)
Zhao X, Boenisch O, Yeung M, Mfarrej B, Yang S, Turka LA et al (2012) Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. Am J Transplant 12(1):90–101. https://doi.org/10.1111/j.1600-6143.2011.03770.x. (PMID: 10.1111/j.1600-6143.2011.03770.x21992708)
Zhao YG, Shi BY, Qian YY, Bai HW, Xiao L, He XY (2014) Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis. Int Urol Nephrol 46(6):1225–1230. https://doi.org/10.1007/s11255-013-0599-4. (PMID: 10.1007/s11255-013-0599-424242738)
فهرسة مساهمة: Keywords: Desensitization therapies; Induction immunosuppression; Rejection treatment; Solid organ transplantation
المشرفين على المادة: 0 (Antibodies, Monoclonal)
0 (Immunosuppressive Agents)
0 (Isoantibodies)
تواريخ الأحداث: Date Created: 20220427 Date Completed: 20220708 Latest Revision: 20220708
رمز التحديث: 20221213
DOI: 10.1007/164_2021_570
PMID: 35474024
قاعدة البيانات: MEDLINE
الوصف
تدمد:0171-2004
DOI:10.1007/164_2021_570